Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo.

Volokhina, Elena B; Bergseth, Grethe; van de Kar, Nicole C A J; van den Heuvel, Lambertus P; Mollnes, Tom Eirik

Volokhina, Elena B; Bergseth, Grethe; van de Kar, Nicole C A J; van den Heuvel, Lambertus P; Mollnes, Tom Eirik.

Afiliação

Volokhina EB; Department of Pediatric Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands.
Bergseth G; Research Laboratory, Nordland Hospital, Bodø, Norway.
van de Kar NC; Department of Pediatric Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands.
van den Heuvel LP; Department of Pediatric Nephrology, and Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands Department of Pediatric Nephrology, University Hospitals, Leuven, Belgium.
Mollnes TE; Research Laboratory, Nordland Hospital, Bodø, Norway Department of Immunology, Oslo University Hospital, K.G. Jebsen Inflammation Research Centre, University of Oslo, Oslo, Norway Faculty of Health Sciences, K.G. Jebsen Thrombosis Research and Expertise Center, University of Tromsø, Tromsø, Norway C

Blood ; 126(2): 278-9, 2015 Jul 09.

Article em En | MEDLINE | ID: mdl-26160188

Assuntos

Anticorpos Monoclonais Humanizados/uso terapêutico; Complemento C5a/imunologia; Síndrome HELLP/terapia; Feminino; Humanos; Gravidez

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Complemento C5a / Síndrome HELLP / Anticorpos Monoclonais Humanizados Limite: Female / Humans / Pregnancy Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google